2025
On March 5, the company signed an EPC contract with Chutian Technology.
On April 11, the company signed a strategic cooperation framework agreement with South Korea’s EpiBiotech.
On April 20, NL003 was granted a U.S. invention patent.
On April 21, the Phase III clinical study results of NL003 were published in Molecular Therapy.
On May 21, the company will exhibit at the 90th National Pharmaceutical Fair.
On July 7, the summary meeting for the Phase III clinical study of NL003 was held in Yanji.
On September 22, the company participated in the 13th North China Vascular Conference.
On November 9, the company was awarded an A-grade excellent rating in the Biejiaosuo information disclosure assessment.
On December 3, the research findings of NL005 were published in Cardiovascular Research.
On December 9, a meeting was held to discuss the clinical trial protocol for NL005IIc.
On December 30, the “Jingjiang Cup” Quality Knowledge Competition concluded.



